Without stimulation and movement, a patient’s muscles can slowly waste away – a major concern among the immobile patient set.
Palo Alto medtech startup Niveus Medical has developed a device that uses electrodes to shock a muscle back to liveliness, and is raising $3.6 million to push that technology further along, according to regulatory filings. In 2011, it raised $2 million from a syndicate that included Band of Angels, Life Science Angels, Sand Hill Angels and others.
One critical component of shortening hospital visits – particularly in the ICU – is to increase mobility, but muscles can deteriorate rapidly when a patient is bedridden and in recovery. Niveus posits its technology can get patients out of the ICU faster, simply by keeping a patient’s muscles engaged even when sedentary
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Its device has received marketing clearance from the FDA, Niveus said. The company asserts a case for its technology:
In the US, there are 6M annual admissions to the ICU. Niveus will initially target the 1.8 million patients who have an ICU stay longer than 5 days. At a conservative price point, these patients create a revenue opportunity exceeding $1.2B in the U.S. alone. Additional opportunities outside of the ICU are envisioned.
The muscle stimulation system has a number of indications: Maintaining or increasing range of motion of the knee joint, preventing or retarding disuse atrophy in the quadriceps, muscle re-education of the quadriceps, relaxation of muscle spasms and increasing local blood circulation.